Summary
The use of more than one drug to control blood pressure may be necessary in up to 50% of hypertensive patients seen in clinical practice. A rational basis for combination therapy includes 1) the use of drugs that act on different physiological systems involved in blood-pressure control and 2) using a second drug to counteract reflex responses, which may limit the effectiveness of the first, and, 3) as is less commonly practiced, the use of low doses of two drugs that act on the same or different physiological systems to avoid the side effects encountered with higher doses of single agents.
The hemodynamic effects of calcium-entry blocking druga and beta-adrenoceptor blockers are complementary and synergism might be anticipated, particularly with the dihydropyridines and beta-blockers, since the latter prevent the short-term reflex increase in sympathetic activity occurring as a consequence of vasodilation.
Although there are many studies advocating the benefits of such combinations, caution is required with combinations of beta-blockers and verapamil or diltiazem because of potential cardiac depressant effects resulting from the more complex effects of these calcium-channel blockers on cardiac myo-cytes and conducting tissue. Such problems would be more likely to be encountered in patients with long-standing hypertension and in whom poor left ventricular function and coro-nary artery disease may be present.
Similar content being viewed by others
References
Veterans Administration Cooperative Study Group on Hypertensive Agents. JAMA 1970;213:1143–1152.
Medical Research Council Working Party. MRC trial of treatment of mild hypertension. Br Med J 1985;291:97–104.
The European Working Party. Mortality and Morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349–1354.
IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol. J Hyperten 1985;3:379–92.
HAPPHY Trial Research Group. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY Trial. J Hyperten 1987;5:561–74.
MAPHY Study. Primary prevention with metoprolol in patients with hypertension. JAMA 1988;259:1976–82.
Zanchetti A, Bartorelli C. Central nervous mechanisms in arterial hypertension: Experimental and clinical evidence. In: GenestJ, KoiwE, KuchelO, eds. Hypertension. New York: McGraw-Hill, 1977:59–76.
Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 1977; 77:1–124.
Man in't Veld AJ, Schalekamp MADH. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol 1982;13:245S-257S.
van Zwieten PA. Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers. Eur Neurol 1986;25(Suppl 1):57–67.
International Society and Federation of Cardiology: Working group on classification of calcium antagonists for cardiovascular disease. Am J Cardiol 1987;60:630–32.
Glossman H, Ferry DR, Lubbecke F, Mewes R, Hofmann F. Calcium channels: Direct identification with radioligand binding studies. Trends Pharmacol Sci 1982;Nov:431–437.
Needleman P, Corr PB, Johnson EM, Drugs used for the treatment of angina: Organic nitrates, calcium channel blockers, and β-adrenergic antagonists. In: Goodman GillmanA, GoodmanLS, RallTW, MuradF, eds. The pharmacological basis of therapeutics, 7th ed. New York: Macmillan, 1985:806–826.
Nayler WG, Horowitz JD, Calcium antagonists: A new class of drugs. Pharmac Ther 1983;20:203–262.
Fleckenstein A. Pharmacology and electrophysiology of calcium antagonists. In: Zanchetti A, Krikler DM, eds. Calcium antagonism in cardiovascular therapy: experience with verapamil Excerpta Medica, 1980:10–29.
Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Eng J Med 1982;307:26:1618–1627.
Godfraind T, Egleme C, Finet M, Jaumin P. The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxicol 1987;61:79–84.
Elara T, Kaufmann R. The voltage and time-dependent effects of (-)-verapamil on the slow inward current in isolated cat ventricular myocardium. J Pharmacol Exp Ther 1978; 207:49–55.
Taira N. Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987;59:24B-29B.
Brouwer RML, Follath F, Buhler FR. Review of the cardiovascular adversity of the calcium antagonist β-blocker combination: Implications for antihypertensive therapy. J Cardiovasc Pharmacol 1985;7(Suppl 4):S38-S44.
Lejeune Ph, Gunselmann W, Hennies L, Heb K, Rittgerodt K, Winn K, Gfrerer G, Schreiber U. Effects of BAY15240, a fixed combination of low dose nifedipine and acebutalol on hypertension: Comparison with standard dose nifedipine. Eur J Pharmacol 1985;28:17–21.
Dargie H, Cleland J, Findlay I, Murray G, McInnes G. Combination of verapamil and beta-blockers in systemic hypertension. Am J Cardiol 1986;57:80D-82D.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sever, P. Combination therapy with calcium-entry blockers and beta-adrenoceptor antagonists in hypertension. Cardiovasc Drug Ther 3 (Suppl 1), 327–332 (1989). https://doi.org/10.1007/BF00148478
Issue Date:
DOI: https://doi.org/10.1007/BF00148478